GTG CEO extends leave through March


By Dylan Bushell-Embling
Tuesday, 07 January, 2014

Genetic Technologies (ASX:GTG) has revealed that CFO and acting CEO Tom Howitt will remain in charge at the company for six weeks longer than planned.

Howitt is filling in for CEO Alison Mew, who took leave in mid October for health-related reasons.

Mew had been scheduled to return in mid January, but the company today announced that she has extended her leave until the end of March. Howitt will continue on as acting CEO in the interim.

Genetic Technologies also announced that it has entered into a fresh settlement as part of its extensive patent enforcement efforts in the US.

The company has agreed to dismiss the suit it filed against US-based Reprogenetics in late 2012 - alleged infringement of GTG’s non-coding DNA patents - after reaching a confidential settlement agreement with the defendant.

The settlement follows a long line of similar agreements reached during 2013.

Genetic Technologies (ASX:GTG) shares were trading unchanged at $0.054 as of around 12.30 pm on Tuesday.

Related News

Algae unlocks a more ethical way to grow cells

Researchers have combined a new type of Queensland algae, Chlorella sp. BDH-1, with...

Oral drug shows promise for treating Barth syndrome

An oral drug called MA-5 can improve both heart and muscle problems in Barth syndrome, a rare...

New route into cells found for gene therapy viruses

Scientists have identified a previously unknown gateway into human cells — a receptor...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd